#ibrance®

European Union Gives Approval to IBRANCE® (palbociclib) for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

November 10, 2016

Pfizer Inc. has announced that the European Commission (EC) has approved IBRANCE® (palbociclib) for treating women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. The approval is for IBRANCE for using in combination with an aromatase inhibitor. It also covers the use of IBRANCE combining…

Pfizer Gets Positive CHMP Opinion for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for The Treatment of HR+/HER2- Metastatic Breast Cancer in Europe

September 16, 2016

Pfizer Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE® (palbociclib) be granted marketing authorization in the European Union (EU) for treating women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-)…

Pfizer Announces Positive Top-Line Results for the Clinical Trial of IBRANCE®

April 19, 2016

Pfizer Inc. has announced positive top-line results from the Phase 3 PALOMA-2 trial for IBRANCE®, an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. The study demonstrated an improvement in progression-free survival (PFS) for the combination of IBRANCE plus letrozole compared with letrozole plus placebo in post-menopausal women with estrogen…